Ex Vivo Compound Screening and Drug Repurposing

CBmed provides a highly automated ex vivo drug/compound screening platform designed for precision medicine approaches and translational oncology. The platform integrates high‑throughput and high‑content screening in a standardized robotic workflow , enabling scalable testing with improved precision and reproducibility. Core components include automated compound transfer (acoustic dispensing), bulk dispensing/plate washing, incubation, plate reading (fluorescence/absorbance/luminescence) and high‑content confocal imaging, supported by flexible software for assay development and optional gene‑expression–based screening.

A central application is functional screening on short‑term cultured patient‑derived tumor cells (PDCs) in 2D and 3D cultures, including tumor spheroids. PDCs are generated from freshly resected tumor tissue and expanded for 1–2 weeks prior to screening; the workflow enables timely results (typically within 3–4 weeks), supporting clinical applicability compared with slower animal model approaches. Screening is performed across multiple compounds and concentrations under high quality control standards, with analysis of high‑throughput datasets to inform response profiling and translational decision‑making.